Literature DB >> 20700107

Personalized versus evidence-based medicine with PET-based imaging.

Sandip Basu1.   

Abstract

In this Perspective the feasibility, scope and impact of integrating PET-based personalized medicine into the evidence-based clinical practice of oncology is discussed. The basic concepts of 'evidence-based medicine' and 'personalized medicine' at times seem contradictory; however, I will discuss, with specific clinical situations as examples, a synergistic and probably incremental link between the two and propose that the result of such integration will ultimately improve patient management. Tailoring therapeutic approaches and regimens by molecular imaging, with PET at its forefront, would enable disease management at the individual level and this modification would hopefully further strengthen the evidence-based approach in oncology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20700107     DOI: 10.1038/nrclinonc.2010.121

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  29 in total

1.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

Review 2.  FDG-PET and beyond: molecular breast cancer imaging.

Authors:  Andrew Quon; Sanjiv S Gambhir
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

3.  Should FDG-PET imaging be considered on a routine basis in clinical trials for carcinoma of esophagus to assure uniformity of protocols among sites?

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

4.  Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer.

Authors:  Sandip Basu; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

Review 5.  Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.

Authors:  R Kumar; H Dhanpathi; S Basu; D Rubello; S Fanti; A Alavi
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 2.346

6.  Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.

Authors:  Carolyn E Reed; David H Harpole; Katherine E Posther; Sandra L Woolson; Robert J Downey; Bryan F Meyers; Robert T Heelan; Homer A MacApinlac; Sin-Ho Jung; Gerard A Silvestri; Barry A Siegel; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 5.209

7.  FDG-PET in staging lung cancer: how does it change the algorithm?

Authors:  A F T Verhagen; G P Bootsma; V C G Tjan-Heijnen; G J van der Wilt; A L Cox; M H J Brouwer; F H M Corstens; W J G Oyen
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

8.  Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.

Authors:  Ulrich Dührsen; Andreas Hüttmann; Karl-Heinz Jöckel; Stefan Müller
Journal:  Leuk Lymphoma       Date:  2009-11

Review 9.  Ten years of rituximab in NHL.

Authors:  Matthew C Winter; B W Hancock
Journal:  Expert Opin Drug Saf       Date:  2009-03       Impact factor: 4.250

10.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

Authors:  K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

View more
  11 in total

1.  Nuclear medicine, scientific publishing and the era of cost containment: what factors hold the key?

Authors:  Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-14       Impact factor: 9.236

Review 2.  (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.

Authors:  Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-16       Impact factor: 9.236

3.  Assessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats.

Authors:  Mario L Fabiilli; Morand R Piert; Robert A Koeppe; Phillip S Sherman; Carole A Quesada; Oliver D Kripfgans
Journal:  Contrast Media Mol Imaging       Date:  2013 Jul-Aug       Impact factor: 3.161

4.  Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR).

Authors: 
Journal:  Insights Imaging       Date:  2011-09-29

5.  Transbilayer phospholipids molecular imaging.

Authors:  Tarik Z Belhocine; Frank S Prato
Journal:  EJNMMI Res       Date:  2011-08-22       Impact factor: 3.138

6.  Emerging clinical applications of PET based molecular imaging in oncology: the promising future potential for evolving personalized cancer care.

Authors:  Vandana K Dhingra; Abhishek Mahajan; Sandip Basu
Journal:  Indian J Radiol Imaging       Date:  2015 Oct-Dec

Review 7.  Positron emission tomography image-guided drug delivery: current status and future perspectives.

Authors:  Rubel Chakravarty; Hao Hong; Weibo Cai
Journal:  Mol Pharm       Date:  2014-06-04       Impact factor: 4.939

8.  Bioavailable copper modulates oxidative phosphorylation and growth of tumors.

Authors:  Seiko Ishida; Pénélope Andreux; Carole Poitry-Yamate; Johan Auwerx; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

9.  Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes.

Authors:  Zihua Zeng; Parag Parekh; Zheng Li; Zheng-Zheng Shi; Ching-Hsuan Tung; Youli Zu
Journal:  Theranostics       Date:  2014-07-19       Impact factor: 11.556

10.  Role of 18F-fluorodeoxyglucose (FDG) and 18F-2-fluorodeoxy sorbitol (FDS) in autoimmune hypophysitis: a case report.

Authors:  Ziren Kong; Yu Wang; Wenbin Ma; Xin Cheng
Journal:  BMC Endocr Disord       Date:  2020-06-09       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.